CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Test: Favipiravir 200 mg (LOQULAR)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug963 Fondaparinux Wiki 1.00
drug2051 Reference: Favipiravir 200 mg (Avigan) Wiki 1.00
drug115 Acetylsalicylic acid Wiki 1.00
drug2522 Tirofiban Injection Wiki 1.00
drug588 Clopidogrel Wiki 0.71

Correlated MeSH Terms (7)

Name (Synonyms) Correlation
D016769 Embolism and Thrombosis NIH 0.58
D004617 Embolism NIH 0.30
D013927 Thrombosis NIH 0.23
D011024 Pneumonia, Viral NIH 0.13
D011014 Pneumonia NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001907 Thromboembolism HPO 0.24
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Loqular 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.

NCT04407000 Bioequivalence Drug: Test: Favipiravir 200 mg (LOQULAR) Drug: Reference: Favipiravir 200 mg (Avigan)

Primary Outcomes

Description: AUC0-tlast of favipiravir

Measure: Primary PK End Points AUC0-tlast

Time: 12 weeks

Description: Cmax of favipiravir

Measure: Primary PK End Points Cmax

Time: 13 weeks

Secondary Outcomes

Description: AUC0-inf of favipiravir

Measure: Secondary PK End Points AUC0-inf

Time: 14 weeks

Description: tmax of favipiravir

Measure: Secondary PK End Points tmax

Time: 15 weeks

No related HPO nodes (Using clinical trials)